Cohort profile: The BiCoVac cohort - a nationwide Danish cohort to assess short and long-term symptoms following COVID-19 vaccination DOI Creative Commons

Christina Bisgaard Jensen,

Kristoffer Torp Hansen, Casper Mailund Nielsen

et al.

European Journal of Epidemiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Abstract BiCoVac is a population-based Danish cohort aiming to examine whether Coronavirus disease 2019 (COVID-19) vaccines are associated with non-specific symptoms beyond the specific protection of COVID-19. Data were collected by four questionnaire surveys between May 2021 and July 2022 distribution was aligned COVID-19 vaccination program. All self-reported information on (e.g., headache, nausea, fatigue). The baseline survey additionally gathered lifestyle health. Survey data combined from registers including test results. A total 911,613 (25% all citizens aged 16 65) randomly sampled for 252,401 initiated questionnaire. Of these, 59% ( n = 149,070) participated in 1st follow-up, 43% 107,655) 2nd 25% 63,737) 3rd follow-up. Women individuals above 40 years age more likely participate. Among vaccinated respondents, 25–38% reported moderate severe immediate following vaccination, varying vaccine doses. Females, younger individuals, those prior symptoms. Results potential did not reveal higher risk involuntary movements among compared unvaccinated individuals. Currently (December 2024), we further investigating effects other exploring characteristics render some susceptible report In addition, long-term being investigated.

Language: Английский

Cohort profile: The BiCoVac cohort - a nationwide Danish cohort to assess short and long-term symptoms following COVID-19 vaccination DOI Creative Commons

Christina Bisgaard Jensen,

Kristoffer Torp Hansen, Casper Mailund Nielsen

et al.

European Journal of Epidemiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Abstract BiCoVac is a population-based Danish cohort aiming to examine whether Coronavirus disease 2019 (COVID-19) vaccines are associated with non-specific symptoms beyond the specific protection of COVID-19. Data were collected by four questionnaire surveys between May 2021 and July 2022 distribution was aligned COVID-19 vaccination program. All self-reported information on (e.g., headache, nausea, fatigue). The baseline survey additionally gathered lifestyle health. Survey data combined from registers including test results. A total 911,613 (25% all citizens aged 16 65) randomly sampled for 252,401 initiated questionnaire. Of these, 59% ( n = 149,070) participated in 1st follow-up, 43% 107,655) 2nd 25% 63,737) 3rd follow-up. Women individuals above 40 years age more likely participate. Among vaccinated respondents, 25–38% reported moderate severe immediate following vaccination, varying vaccine doses. Females, younger individuals, those prior symptoms. Results potential did not reveal higher risk involuntary movements among compared unvaccinated individuals. Currently (December 2024), we further investigating effects other exploring characteristics render some susceptible report In addition, long-term being investigated.

Language: Английский

Citations

0